Dioseve
Develops iPS cell-derived co-culture technology to improve oocyte maturation and reduce IVF treatment burden
$7MSeries A+
Role not disclosedLoading investors…
Activity from announced rounds
Develops iPS cell-derived co-culture technology to improve oocyte maturation and reduce IVF treatment burden
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy
Pitching Pangaea Ventures? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room